EUVIMEDEUVIMED entdecken
Crossref

First-in-Human PET/CT Imaging of FXX489, a Second-Generation Cyclic Peptide FAP Inhibitor: A Translational Exploratory Study

Yi Tian, Leyi Ying, Yuxiang Wang, Shu Wang, Xuefei Li, Yaming Li, Xuena Li iD

Molecular Pharmaceutics · 02.11.2026 · 23 (11) · 5630-5641

DOI: 10.1021/acs.molpharmaceut.6c00763 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 25.09.2026. Verfasst von Yi Tian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The First Hospital of China Medical University, Shenyang110001, Liaoning, China. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Peptides, Cyclic, Radiopharmaceuticals, Gelatinases. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Liaoning Provincial Science and Technology Program Joint Plan Project, Liaoning Revitalization Talents Program, National Natural Science Foundation of China (NSFC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sufficient tumor uptake and retention, and high tumor-to-kidney ratio are highly relevant for fibroblast activation protein (FAP)-targeted tracers as imaging companions for theranostic development. Although FAP-2286 improves tumor retention versus early-generation FAPI tracers, its extended renal residence limits its application as a radiopharmaceutical therapy. We benchmarked FXX489, a next-generation cyclic peptide FAP ligand, against FAP-2286 preclinically and evaluated first-in-human [68Ga]Ga-FXX489 PET/CT to support its translational development for FAP-directed theranostics. [68Ga]Ga-FXX489 showed stronger FAP affinity than [68Ga]Ga-FAP-2286, including higher cellular uptake, lower efflux, and lower IC50. In HT-1080-hFAP xenografts, [68Ga]Ga-FXX489 achieved higher tumor uptake and retention on micro-PET and ex vivo biodistribution, and a higher tumor-to-kidney ratio. In patients (n = 10), [68Ga]Ga-FXX489 was well tolerated, and detected all 12 primary lesions (mean SUVmax, 11.20 ± 3.24) and all 42 metastatic lymph nodes (100% [42/42] vs 74% [31/42] for [18F]FDG, P < 0.001), while visualizing gastric cancer lesions with higher uptake than [18F]FDG in a paired comparison. [68Ga]Ga-FXX489 improves tumor retention and tumor-to-kidney ratio compared to [68Ga]Ga-FAP-2286 while maintaining specific FAP targeting. First-in-human [68Ga]Ga-FXX489 PET/CT shows promising detection of primary and metastatic lesions, supporting further clinical applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyPeptides, CyclicRadiopharmaceuticalsGelatinasesMembrane ProteinsHumansAnimalsMiceFibroblast Activation Protein AlphaFemaleTissue DistributionEndopeptidasesSerine EndopeptidasesCell Line, TumorGallium RadioisotopesMaleXenograft Model Antitumor AssaysMice, Nude

Stichwörter der Autor:innen

FAP-2286FXX489PET/CTcyclic peptide inhibitorfibroblast activation proteintheranostics

Substanzen

Peptides, CyclicFibroblast Activation Protein AlphaRadiopharmaceuticalsEndopeptidasesSerine EndopeptidasesGallium RadioisotopesGelatinasesMembrane Proteins

Autor:innen und Institutionen

  • Department of Nuclear Medicine, The First Hospital of China Medical University, Shenyang110001, Liaoning, China.

ORCID-Profile: Xuena Li

Förderung

  • Liaoning Provincial Science and Technology Program Joint Plan Project
  • Liaoning Revitalization Talents Program
  • National Natural Science Foundation of China (NSFC)

Zitieren

APA

Tian, Y., Ying, L., Wang, Y., Wang, S., Li, X., Li, Y., & Li, X. (2026). First-in-Human PET/CT Imaging of FXX489, a Second-Generation Cyclic Peptide FAP Inhibitor: A Translational Exploratory Study. Molecular Pharmaceutics, 23(11), 5630-5641. https://doi.org/10.1021/acs.molpharmaceut.6c00763

Vancouver

Tian Y, Ying L, Wang Y, Wang S, Li X, Li Y, et al. First-in-Human PET/CT Imaging of FXX489, a Second-Generation Cyclic Peptide FAP Inhibitor: A Translational Exploratory Study. Molecular Pharmaceutics. 2026;23(11):5630-5641. doi:10.1021/acs.molpharmaceut.6c00763

BibTeX
@article{Tian2026,
  author = {Tian, Yi and Ying, Leyi and Wang, Yuxiang and Wang, Shu and Li, Xuefei and Li, Yaming and Li, Xuena},
  title = {First-in-Human PET/CT Imaging of FXX489, a Second-Generation Cyclic Peptide FAP Inhibitor: A Translational Exploratory Study},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  volume = {23},
  number = {11},
  pages = {5630--5641},
  doi = {10.1021/acs.molpharmaceut.6c00763}
}
Kostenlos starten →